User:Madison Unger/Sandbox 1
From Proteopedia
(Difference between revisions)
| Line 8: | Line 8: | ||
== Structure == | == Structure == | ||
=== Overall Structure === | === Overall Structure === | ||
| - | ACAT is a tetramer composed of a [http://en.wikipedia.org/wiki/Protein_dimer dimer] of a dimer, but is able to perform its function solely as a <scene name='87/877507/Dimer/1'>dimer</scene>. [[Image:Tetramer_dimer_of_dimer.png|400px|left|thumb|Figure 2: Tetrameric dimer of dimer for ACAT]]There are <scene name='87/877506/9_tm_helices_per_monomer/1'>nine transmembrane helices</scene> in each domain which create a tunnel for the active site. There are also three helices found on the intracellular side (IH1, IH2, and IH3) and one helix on the extracellular side (EH1). The active site contains three tunnels – the transmembrane tunnel for cholesterol entrance, the cytosolic tunnel for acyl-CoA entrance, and the lumen tunnel for cholesterol ester exit. ACAT also has an amino-terminal cytosolic domain (NTD) that is important for tetramerization of this protein. | + | ACAT is a tetramer composed of a [http://en.wikipedia.org/wiki/Protein_dimer dimer] of a dimer, but is able to perform its function solely as a <scene name='87/877507/Dimer/1'>dimer</scene> (Fig. 2). [[Image:Tetramer_dimer_of_dimer.png|400px|left|thumb|Figure 2: Tetrameric dimer of dimer for ACAT]]There are <scene name='87/877506/9_tm_helices_per_monomer/1'>nine transmembrane helices</scene> in each domain which create a tunnel for the active site. There are also three helices found on the intracellular side (IH1, IH2, and IH3) and one helix on the extracellular side (EH1). The active site contains three tunnels – the transmembrane tunnel for cholesterol entrance, the cytosolic tunnel for acyl-CoA entrance, and the lumen tunnel for cholesterol ester exit. ACAT also has an amino-terminal cytosolic domain (NTD) that is important for tetramerization of this protein. |
=== Important Residues === | === Important Residues === | ||
An important residue in the ACAT active site is His460, a Histidine, which is located in the middle of the tunnels. It is thought that His460 is located on TM7 (Qian et al.). When converting to a cholesteryl ester, the <scene name='87/877507/H460_labeled/4'>His460</scene> acts as a catalytic base that deprotonates the cholesterol. An asparagine <scene name='87/877505/Asn241/2'>Asn421</scene> is another important residue in the reaction that is able to form a hydrogen bond with acyl-CoA for stabilization. | An important residue in the ACAT active site is His460, a Histidine, which is located in the middle of the tunnels. It is thought that His460 is located on TM7 (Qian et al.). When converting to a cholesteryl ester, the <scene name='87/877507/H460_labeled/4'>His460</scene> acts as a catalytic base that deprotonates the cholesterol. An asparagine <scene name='87/877505/Asn241/2'>Asn421</scene> is another important residue in the reaction that is able to form a hydrogen bond with acyl-CoA for stabilization. | ||
| Line 27: | Line 27: | ||
== Known Inhibitors == | == Known Inhibitors == | ||
| - | Guan et al. has identified a small molecule inhibitor of ACAT, known as CI-976, which belongs to the fatty acyl amide analog molecule family. <scene name='87/877508/Ci-976_inhibitor/2'>CI-976</scene> is a competitive inhibitor in the ACAT active site and was found to inhibit ACAT in a dose-dependent manner. CI-976 has a trimethoxyphenol head that interacts with the catalytic residue, His460. This head also interacts with Tyr416 and Tyr417. The long-chain tail of CI-476 also interacts with specific residues, notably Leu377 and Leu515. [[Image:Inhibitor structureCI9.png|350px|left|thumb|Figure 4: Structure of known ACAT inhibitor]]Overall, it was determined that because CI-976 binds in the active site, it inhibits ACAT by preventing the binding of the natural substrate into the active site<ref name="Guan" />. | + | Guan et al. has identified a small molecule inhibitor of ACAT, known as CI-976, which belongs to the fatty acyl amide analog molecule family. <scene name='87/877508/Ci-976_inhibitor/2'>CI-976</scene> is a competitive inhibitor in the ACAT active site and was found to inhibit ACAT in a dose-dependent manner (Fig. 4). CI-976 has a trimethoxyphenol head that interacts with the catalytic residue, His460. This head also interacts with Tyr416 and Tyr417. The long-chain tail of CI-476 also interacts with specific residues, notably Leu377 and Leu515. [[Image:Inhibitor structureCI9.png|350px|left|thumb|Figure 4: Structure of known ACAT inhibitor]]Overall, it was determined that because CI-976 binds in the active site, it inhibits ACAT by preventing the binding of the natural substrate into the active site<ref name="Guan" />. |
== Medical Relevance == | == Medical Relevance == | ||
The mechanism of ACAT is essential for cholesterol storage and cholesterol transfer through the plasma because cholesteryl ester is the primary form of cholesterol used for these events. Additionally, ACAT can use a variety of different sterol molecules besides cholesterol as substrates and activators. Because of its biological importance, ACAT has been linked to [http://en.wikipedia.org/wiki/Atherosclerosis atherosclerosis], [http://en.wikipedia.org/wiki/Alzheimer%27s_disease Alzheimer’s disease], and cancer as a potential drug target for treatment of these diseases<ref>PMID:17986151</ref>. Various studies have looked into ACAT inhibition and how that inhibition treats or prevents certain diseases, such as reducing the size and metastasis of certain tumors<ref>PMID:27132508</ref> and reducing the formation of plaques in atherosclerosis<ref>PMID:11100106</ref>. ACAT is an important target for these diseases due to its functional relevance in cholesterol metabolism. | The mechanism of ACAT is essential for cholesterol storage and cholesterol transfer through the plasma because cholesteryl ester is the primary form of cholesterol used for these events. Additionally, ACAT can use a variety of different sterol molecules besides cholesterol as substrates and activators. Because of its biological importance, ACAT has been linked to [http://en.wikipedia.org/wiki/Atherosclerosis atherosclerosis], [http://en.wikipedia.org/wiki/Alzheimer%27s_disease Alzheimer’s disease], and cancer as a potential drug target for treatment of these diseases<ref>PMID:17986151</ref>. Various studies have looked into ACAT inhibition and how that inhibition treats or prevents certain diseases, such as reducing the size and metastasis of certain tumors<ref>PMID:27132508</ref> and reducing the formation of plaques in atherosclerosis<ref>PMID:11100106</ref>. ACAT is an important target for these diseases due to its functional relevance in cholesterol metabolism. | ||
Revision as of 19:26, 12 April 2021
Human Acyl-CoenzymeA
| |||||||||||
References
- ↑ 1.0 1.1 Qian H, Zhao X, Yan R, Yao X, Gao S, Sun X, Du X, Yang H, Wong CCL, Yan N. Structural basis for catalysis and substrate specificity of human ACAT1. Nature. 2020 May;581(7808):333-338. doi: 10.1038/s41586-020-2290-0. Epub 2020 May, 13. PMID:32433614 doi:http://dx.doi.org/10.1038/s41586-020-2290-0
- ↑ Cases S, Novak S, Zheng YW, Myers HM, Lear SR, Sande E, Welch CB, Lusis AJ, Spencer TA, Krause BR, Erickson SK, Farese RV Jr. ACAT-2, a second mammalian acyl-CoA:cholesterol acyltransferase. Its cloning, expression, and characterization. J Biol Chem. 1998 Oct 9;273(41):26755-64. doi: 10.1074/jbc.273.41.26755. PMID:9756919 doi:http://dx.doi.org/10.1074/jbc.273.41.26755
- ↑ 3.0 3.1 Guan C, Niu Y, Chen SC, Kang Y, Wu JX, Nishi K, Chang CCY, Chang TY, Luo T, Chen L. Structural insights into the inhibition mechanism of human sterol O-acyltransferase 1 by a competitive inhibitor. Nat Commun. 2020 May 18;11(1):2478. doi: 10.1038/s41467-020-16288-4. PMID:32424158 doi:http://dx.doi.org/10.1038/s41467-020-16288-4
- ↑ Rogers MA, Liu J, Song BL, Li BL, Chang CC, Chang TY. Acyl-CoA:cholesterol acyltransferases (ACATs/SOATs): Enzymes with multiple sterols as substrates and as activators. J Steroid Biochem Mol Biol. 2015 Jul;151:102-7. doi: 10.1016/j.jsbmb.2014.09.008., Epub 2014 Sep 12. PMID:25218443 doi:http://dx.doi.org/10.1016/j.jsbmb.2014.09.008
- ↑ Hartmann T, Kuchenbecker J, Grimm MO. Alzheimer's disease: the lipid connection. J Neurochem. 2007 Nov;103 Suppl 1:159-70. doi: 10.1111/j.1471-4159.2007.04715.x. PMID:17986151 doi:http://dx.doi.org/10.1111/j.1471-4159.2007.04715.x
- ↑ Li J, Gu D, Lee SS, Song B, Bandyopadhyay S, Chen S, Konieczny SF, Ratliff TL, Liu X, Xie J, Cheng JX. Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer. Oncogene. 2016 Dec 15;35(50):6378-6388. doi: 10.1038/onc.2016.168. Epub 2016 May , 2. PMID:27132508 doi:http://dx.doi.org/10.1038/onc.2016.168
- ↑ Rudel LL, Shelness GS. Cholesterol esters and atherosclerosis-a game of ACAT and mouse. Nat Med. 2000 Dec;6(12):1313-4. doi: 10.1038/82110. PMID:11100106 doi:http://dx.doi.org/10.1038/82110
Student Contributors
- Leah Goehring
- Gabby Smith
- Anna Campbell
